A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Omega-3 carboxylic acids (Primary)
- Indications Hypertriglyceridaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2017.